Back to Screener

Healthcare

Telomir Pharmaceuticals, Inc. Common Stock(TELO)

Live Price

Offline

$1.42

+13.60% today

1Y Change

-23.08%

Window

Jun 23, 2025 โ†’ May 29, 2026

Market Cap
$50.00M
Revenue Growth
0.0%
EPS Growth
+41.1%
Dividend Yield
0.0%

Coverage: 236 bars ยท Jun 23, 2025 โ†’ May 29, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Telomir Pharmaceuticals, Inc. Common Stock (TELO) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $1.42 and down 23.1% across the available one-year price window (Jun 23, 2025 โ†’ May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +41.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +41.1%, free cash flow +27.3% with operating margin 0.0% and ROIC -178.2%. Stock Foundry combines TELO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

0.0% vs +7.6% peer median

Operating Margin

Below sector median

0.0% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2026 was reported on May 13, 2026, but the surprise data is still limited.

The setup is mixed rather than one-directional

Revenue is 0.0% and EPS is +41.1%, while operating margin sits near 0.0%.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged +1.2% over the next 5 trading days and finished higher after 2 of those reports.

View quarter-by-quarter reaction table
QuarterEPS ฮ”1D5D20D
2026
May 13, 2026
โ€”+3.3%+6.5%โ€”
2026
Mar 17, 2026
+14.3%-5.9%-5.2%-0.7%
2025
Nov 10, 2025
+57.1%+3.6%+2.2%+4.4%

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

TELO

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

TELO Max Drawdown

-52.84%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for TELO and SPY.

Calendar-year return history is still loading or unavailable.
Telomir Pharmaceuticals, Inc. Common Stock logo

Company Overview

Telomir Pharmaceuticals, Inc. Common Stock

NASDAQ Capital Market

Baltimore, FL, US
Visit telomirpharma.comCall IR(737)-289-0835

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Leadership
Erez Aminov
IPO Date
Apr 9, 2019
Employees
1
Street Address
855 N Wolfe Street
Mailing
Baltimore, FL, 21205
Region
Baltimore, FL, US
Reporting Currency
USD
Investor Line
(737)-289-0835
Last Updated
May 5, 2026
CIK: 0001971532ISIN: US87975F1049CUSIP: 87975F104
Reports in USDSEC Registered

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
โ€”
Price/Book
8.1

Growth

Revenue
0.0%
EPS
+41.1%
Free Cash Flow
+27.3%

Profitability

Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-315.2%
ROIC
-178.2%

Balance Sheet

Debt/Equity
โ€”
Current Ratio
5.14

Earnings Reports

๐Ÿ“… Last reportedMay 13, 2026
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
May 13, 26
โ€”
Est -0.07
โ€”
โ€”
Est โ€”
โ€”
โ€”
Mar 17, 26
โœ“
-0.06
Est -0.07
+14.3%
โ€”
Est โ€”
โ€”
โ€”
Nov 10, 25
โœ“
-0.03
Est -0.07
+57.1%
โ€”
Est โ€”
โ€”
โ€”
Aug 14, 25
โœ—
-0.17
Est -0.08
-112.5%
โ€”
Est โ€”
โ€”
โ€”
May 14, 25
โœ“
-0.07
Est -0.10
+30.0%
โ€”
Est โ€”
โ€”
โ€”
Feb 4, 25
โœ—
-0.10
Est -0.05
-100.0%
18793.5B
Est โ€”
โ€”
โ€”
Nov 12, 24
โœ—
-0.20
Est -0.05
-300.0%
โ€”
Est โ€”
โ€”
โ€”
Aug 13, 24
-0.05
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
May 13, 24
-0.23
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Mar 29, 24
-0.32
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Sep 30, 23
-0.06
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Jun 30, 23
-0.05
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Mar 31, 23
-0.02
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Dec 31, 22
-0.02
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Sep 29, 22
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Jun 29, 22
-0.00
Est โ€”
โ€”
โ€”
Est โ€”
โ€”

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks